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Abstract
Background: Long interspersed element-1 (LINE-1, L1) is the major driver of mobile DNA activity in modern
humans. When expressed, LINE-1 loci produce bicistronic transcripts encoding two proteins essential for
retrotransposition, ORF1p and ORF2p. Many types of human cancers are characterized by L1 promoter
hypomethylation, L1 transcription, L1 ORF1p protein expression, and somatic L1 retrotransposition. ORF2p encodes
the endonuclease and reverse transcriptase activities required for L1 retrotransposition. Its expression is poorly
characterized in human tissues and cell lines.
Results: We report mass spectrometry-based tumor proteome profiling studies wherein ORF2p eludes detection. To
test whether ORF2p could be detected with specific reagents, we developed and validated five rabbit monoclonal
antibodies with immunoreactivity for specific epitopes on the protein. These reagents readily detect ectopic ORF2p
expressed from bicistronic L1 constructs. However, endogenous ORF2p is not detected in human tumor samples or
cell lines by western blot, immunoprecipitation, or immunohistochemistry despite high levels of ORF1p expression.
Moreover, we report endogenous ORF1p-associated interactomes, affinity isolated from colorectal cancers, wherein
we similarly fail to detect ORF2p. These samples include primary tumors harboring hundreds of somatically
acquired L1 insertions. The new data are available via ProteomeXchange with identifier PXD013743.
Conclusions: Although somatic retrotransposition provides unequivocal genetic evidence for the expression of
ORF2p in human cancers, we are unable to directly measure its presence using several standard methods.
Experimental systems have previously indicated an unequal stoichiometry between ORF1p and ORF2p, but in vivo,
the expression of these two proteins may be more strikingly uncoupled. These findings are consistent with
observations that ORF2p is not tolerable for cell growth.
Background
Mobile elements make up nearly half of the human gen-
ome [1, 2]. The most prevalent sequences are retrotran-
sposons, which propagate via RNA intermediates, and of
these, modern activity resides with the Long INterspersed
Element-1 (LINE-1, L1) sequences and those elements
mobilized by L1 proteins in trans (reviewed in [3–5]). L1
is the only autonomous (protein-coding), functional retro-
transposon in humans, and each of us inherits a distinct
complement of active elements [6]. Mobilization occurs
after a retrotransposition-competent L1 is transcribed,
translated into proteins encoded by its open reading
frames (ORFs), ORF1p [7, 8] and ORF2p, and packaged
into a ribonucleoprotein (RNP) complex [9, 10]. ORF2p
encodes an endonuclease [11] that cuts the genomic DNA
target site and a reverse transcriptase [12] that generates
L1 cDNA.
Many malignant tissues undergo L1 promoter hypo-
methylation [13–17] and permit L1 expression and
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somatic retrotransposition [13, 14, 18–26]. Both targeted
and genome-wide sequencing efforts have identified
thousands of de novo insertions that have occurred
across hundreds of human cancers. Several groups have
shown that L1 ORF1p expression is a hallmark of many
different cancers [23, 27]. Of these many cancer types, it
has been shown that L1 upregulation is induced early in
the development of ovarian cancers, where ORF1p accu-
mulation is evident within precursor lesions of the
fallopian tube [15, 28]. L1 retrotransposition can also
contribute directly to cellular transformation; in colon
cancers, acquired L1 insertions are known to cause driv-
ing mutations in the adenomatous polyposis coli (APC)
tumor suppressor [13, 29].
ORF2p is strictly required for retrotransposition [30],
and so its expression in human malignancies can be in-
ferred. Whether the protein can be directly detected has
been a matter of some debate. In experimental systems,
ORF2p is translated from the bicistronic transcript
through an unconventional mechanism [31]. Compared
to ORF1p, ectopically expressed ORF2p accumulates in
substoichiometric amounts (ORF1p:ORF2p ratio > 30:1)
and may be restricted to a subset of cells within a popu-
lation [9, 10, 32]. Reports of endogenously expressed
ORF2p have been more limited than ORF1p [33]. To
our knowledge, to date, two groups have independently
reported development of monoclonal antibodies recog-
nizing human ORF2p, both using BALB/c mice. One re-
agent, developed by Belancio and colleagues [34], was
reported to detect ectopically expressed ORF2p only. A
second reagent, developed by Sciamanna, Spadafora, and
colleagues [35], was reported to detect endogenous
ORF2p in several malignant tissues where ORF1p ex-
pression has been reported. However, questions have
been raised about the specificity of this reagent (Logan
and colleagues). The difficulty directly detecting ORF2p
may not simply be a matter of lacking exceptional
affinity reagents for sensitive and specific western
blotting. As we describe in this report, ORF2p has
also eluded robust detection in a systematic, mass
spectrometry-based tumor proteome sequencing effort
(breast and ovary analyzed here) and in our own im-
munoprecipitations of ORF1p from resected patient
colorectal tumors; this, when ORF1p is robustly de-
tected and captured.
Here, we present our perspective on ORF2p detection,
including results obtained searching for ORF2p in can-
cer proteomes as well as probing and analyzing tissue
sections and immunoprecipitates. We describe the de-
velopment of additional reagents to detect ORF2p: 5
rabbit monoclonal antibodies. Western blotting, immu-
noprecipitation, immunohistochemistry, and immuno-
fluorescence demonstrate the utility of these reagents in
experimental systems with ectopic LINE-1 expression.
However, we have not yet detected endogenous ORF2p
using these approaches; moreover, we report endogen-
ous ORF1p-associated interactomes, affinity isolated
from colorectal cancers (CRC), in which ORF2p was not
found. These studies indicate that ORF2p is expressed at
presently undetectable levels in human cancers, corrob-
orating previous studies by Sokolowski et al.[34].
Results
Detecting ORF1p and ORF2p peptides in tumor mass
spectrometry data
We reanalyzed data from Clinical Proteomics Tumor
Analysis Consortium (CPTAC) to assess L1 ORF1p and
ORF2p protein production in tumors. CPTAC has gen-
erated deep mass spectrometry based proteomics data
from treatment naive breast [36] and ovarian [37] tu-
mors using isobaric labeling and extensive prefractiona-
tion with alkaline reversed-phase chromatography
followed by inline (acidic) reversed-phase chromatog-
raphy and Orbitrap mass spectrometry. For the detec-
tion of ORF1p and ORF2p peptides, we constructed a
protein sequence collection that, in addition to human
proteins from Ensembl, also included high confidence
LINE-1 protein coding sequences from L1Base2 [38],
and used the X! Tandem [39] search engine with the cu-
rated databases and the same search parameters as Rug-
gles et al. [40].
We observed ORF1p in most breast and ovarian tu-
mors (Fig. 1a, with several peptides observed for the ma-
jority of tumors; see Fig. 1b and c for two examples of
quality ORF1p peptide spectrum matches [PSMs]), but
there was no clear evidence for ORF2p. Even when we
relaxed the filters, the potential evidence for ORF2p pep-
tides was questionable and the majority of PSMs were
semi-tryptic and had borderline e-values (≈ 0.01). We
also inspected the potential ORF2p PSMs manually and
rejected them because they had several large peaks that
could not be explained by fragmentation of the assigned
ORF2p peptide. The best ORF2p PSM and only potential
evidence for ORF2p that was not rejected is shown in
Fig. 1d, but this peptide is short and still has two prom-
inent peaks that are not explained by the sequence. In
summary, we can reliably observe ORF1p in breast and
ovarian tumors using deep mass spectrometry-based
proteomics, but, in contrast, the evidence for detection
of ORF2p is inconclusive.
Monoclonal antibodies detect human LINE-1 ORF2
protein
To pursue targeted ORF2p detection methods, we chose
the retrotransposition-competent L1RP sequence as an
immunogen for generating ORF2p monoclonal anti-
bodies. L1RP is part of the highly active Ta-1d subfamily
of L1, which encompasses the vast majority of hot L1 s
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found in humans (including LRE3, L1RP, L1.3) [41–43].
Prior to immunization in rabbits, we expressed tagged
ORF2p fragments from bacteria, one fragment with the
endonuclease domain (EN, amino acids 1–238, His6 tag)
and one fragment containing the reverse transcriptase do-
main and surrounding sequence (RT, amino acids 238–
1061, tagged with mannose binding protein/MBP or a small
ubiquitin-like modifier/SUMO) (Fig. 2a). We also expressed
full-length Flag-tagged ORF2p (ORF2-3xFlag) in Tet-On
human embryonic kidney-293T (HEK-293TLD) cells to
screen immune sera. We confirmed fragment purity after
Nickel or size-exclusion chromatography (Fig. 2b).
For EN-targeting antibodies, we immunized and
boosted two rabbits with EN-His6 fragments, then
screened hybridoma supernatants by ELISA against puri-
fied EN domain and subsequently ORF2-3xFlag. We
Fig. 1 LINE-1 Peptide Detection in Tumor Mass Spectrometry Data. (a) ORF1p peptides observed in CPTAC breast and ovarian tumors. Each column
represents a tumor-derived MS dataset (102 fuchsia-colored columns for breast tumors and 176 sea foam-colored columns for ovarian tumors)
analyzed for the presence of L1 ORF peptides. ORF1 peptides, displayed at the right, mark rows. A red tick indicates that the given peptide was
detected as present in the according tumor sample (white space: peptide not detected). Highest quality PSMs that were observed for (b, c) ORF1p
and (d) ORF2p are displayed. Precursor ion related peaks are shown in yellow, y-ions in red, b-ions in blue, and unassigned ions in black
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used the same strategy for RT-targeting antibodies, but
used MBP-RT to stimulate the primary immune re-
sponse and boosted with SUMO-RT to avoid MBP-
specific antibody generation. We counter-screened
against MBP and SUMO immunoreactivity to identify
hybridomas with reactivity for ORF2p (Fig. 2c). Hybrid-
oma supernatants were then tested for their ability to
detect ORF2-3xFlag by western blot (Fig. 2d), IP (Fig. 2e),
immunofluorescence (IF, Fig. 2f), and immunohistochem-
istry (IHC, Fig. 2g). We used Flag-antibody as a control to
determine whether our ORF2p antibodies detected ORF2-
3xFlag. Five monoclonal antibodies (mAbs) were selected
based on their ability to detect full-length ORF2-3xFlag by
each modality: MT5, MT9, MT11, MT49, and MT69.
Fig. 2 Production of monoclonal ORF2p antibodies. a Expression constructs used to generate antigens for ORF2p antibody production. b
Coomassie-stained protein electrophoresis gels illustrating purity of ORF2p antigens used in antibody generation. c Immunization strategy to
produce rabbit monoclonal antibodies. d Western blot detection of overexpressed ORF2p-3xFlag obtained from HEK-293TLD cells transfected with
pLD561 (shown in panel a) using 5 different monoclonal antibodies (Ab) compared to anti-Flag. e Immunoprecipitation of ORF2p-3xFlag using 3
antibodies. f Immunofluorescence imaging of HEK-293TLD cells expressing ORF2p-3xFlag showing co-localization with anti-Flag antibody. g
Immunohistochemistry of HEK-293TLD cells expressing ORF2p-3xFlag with 4 monoclonal antibodies compared to anti-Flag. h Above, overview of
PhIP-Seq. A phage library expresses protein epitopes from the protein-coding genome, which are affinity purified with ORF2p antibodies. DNA
sequences are then isolated and sequenced to identify the genes encoding the peptides. Below, results from five monoclonal antibodies
targeting ORF2p. In each instance, the greatest affinity of the ORF2p monoclonal antibodies is for peptides encoded by L1Hs ORF2p
peptides. EN = endonuclease, RT = reverse transcriptase, MBP =mannose binding protein, SUMO = small ubiquitin-like modification
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ORF2p antibodies are specific for human-specific LINE-1
(L1Hs)
To assess the specificity of antibodies for L1Hs, we
employed Phage-ImmunoPrecipitation Sequencing
(PhIP-Seq) [44–46]. We obtained all annotated repeats
in the human genome from RepeatMasker and con-
structed a representational phage-display library which
was used in combination with a previously constructed
pan human proteome library [47]. The RepeatMasker
peptidome was tiled from N- to C-terminus using 56
amino acid peptides with 28 amino acid overlaps. PhIP-
Seq enabled us to determine both on- and off-target re-
activities of each antibody by sequencing library IPs (Fig.
2h). Each of the five mAbs pulled down several peptides
encoded by L1Hs sequences with high significance
across both replicates. IP of L1Hs-derived peptides was
orders of magnitude more significant compared to any
other peptide encoded by the unique and repeat human
genome included in the phage libraries. Based on these
data, we conclude that these mAbs have minimal off-
target reactivity, suggesting that these mAbs should be
highly specific to the L1Hs ORF2p.
ORF2p antibodies identify non-overlapping epitopes
There are several hundred potentially active L1 loci with
intact open reading frames that have been characterized
in modern humans [6, 48], and these sequences are
highly identical to one another at both the nucleotide
and amino acid level. The specific repertoire of L1 loci
that is expressed varies among individuals, and by cell or
tissue type [13, 14, 49, 50]. To evaluate the potential of
our mAbs to detect proteins originating from distinct
copies of L1Hs, we mapped the specific epitopes recog-
nized by each antibody and evaluated the conservation
of each epitope among L1Hs loci.
We mapped target epitopes using a peptide array of
overlapping 15-mers tiling the length of ORF2p. We in-
cubated these arrays with each antibody and then used
secondary antibodies conjugated to horseradish peroxid-
ase to identify which peptides were identified. Epitopes
were identified as the largest contiguous stretch of
amino acids that showed mAb binding over background
(Fig. 3a). The linear epitopes ranged in length from 6 to
14 amino acids. Each of the 5 epitopes mapped to a
discrete, non-overlapping segment of ORF2p in a man-
ner consistent with the purified protein fragments we
used for rabbit immunization. The MT49 epitope
(DRSTRQ) and MT69 epitope (LHQADLID) occur adja-
cent to one another and target amino acids on the
surface of the endonuclease domain according to a pub-
lished crystal structure [51]. Both the MT9 epitope
(KASRRQEITKIRAE) and MT11 epitope (KELEKQEQT)
are located between the annotated EN and RT domains,
whereas MT5 identifies an epitope (QDIGVGKD) ~300
amino acids from the C terminus, adjacent to the C
domain.
To validate these epitopes, we pre-incubated mAbs
with blocking peptides and attempted IP of ORF2-
3xFlag. We found a concentration-dependent blocking
activity of each peptide on its corresponding mAb; a
range of 10–1000-fold excess peptide was required to
achieve this effect depending on the mAb (Fig. 3b).
These findings confirm that these epitopes are the anti-
body targets. PhIP-Seq data were also consistent with
these being the cognate epitopes recognized by each
antibody. Finally, we complemented our finding of anti-
body specificity by PhIP-Seq by performing a BLAST
search of these epitopes, which revealed that the only
perfect matches in the human genome belong to L1
ORF2p sequences.
ORF2p mAbs are sensitive for many genomic source
elements
To evaluate the occurrence of these epitopes in naturally-
occurring L1 sequences, we used a census of fixed and
commonly-occurring potentially protein-coding L1 ele-
ments found in the hg38 reference genome build. We
focused on those with intact ORF2 reading frames as
previously annotated by L1Base [38, 52]. We performed
clustal alignments for two non-overlapping sets of these
elements, one consisting of 146 full-length loci (111 L1Hs,
35 L1PA2) and one with 107 ORF2-intact loci. We
included consensus sequences of the youngest human-
specific L1 (L1Hs) and next-youngest primate-specific L1
(L1PA2) as well as the sequence of L1RP – the antigen
against which our mAbs were raised – to compare se-
quences of the immunogen used for antibody generation
against those of other genomic L1 loci. Full-length, intact
LINEs are predominantly of the species-specific L1Hs
subfamily, but include some older, primate-specific L1
elements. As expected, full-length and ORF2-intact L1
amino acid sequences are nearly identical for this set
(Additional file 1: Figure S1). L1RP-encoded ORF2p is
1275 amino acids long. Individual, full-length L1 elements
had open reading frames that differed from this on
average by 16 amino acid variants (1.25%, range 1–61,
Additional file 1: Figure S1), and ORF2-intact L1 loci
differed on average by 32 amino acid variants (2.5%, range
2–79, Additional file 1: Figure S1).
To assess which of the several hundred reference
L1Hs loci could be detected by our mAbs, we used these
clustal alignments to evaluate the proportion of L1 loci
matching each mAb epitope (Fig. 3c). For each epitope,
most full-length L1 loci have amino acid sequences that
are 100% identical. The MT11 epitope (KELEKQEQT)
and MT9 epitope (KASRRQEITKIRAE) similarly occur
nearly universally in ORF2-intact L1 sequences. The
greatest discrepancy occurred in the MT5 epitope
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(QDIGVGKD), where amino acid position 990, which
tends to be universal in intact, full-length L1 sequences,
is not consistently found in elements selected only for
an intact ORF2. Position 990 is typically a valine in
L1Hs sequences and a methionine in older elements
such as L1PA2 due to a G > A nucleotide substitution
(ORF2 position 2968). We tested whether substituting
the L1Hs valine for methionine was sufficient to pre-
clude antibody recognition of the epitope. We created
Flag-tagged L1RP ORF2p with an M990 substitution,
expressed both protein variants in HEK-293TLD, and
performed a western blot using both MT5 and anti-Flag
antibodies (Fig. 3d). We detected no signal from MT5 or
anti-Flag in untransfected cells. We detected both V990
and M990 variants with both anti-Flag and MT5 anti-
bodies. The M990 variant was detected at a weaker rela-
tive intensity by MT5 compared to anti-Flag, indicating
a reduced affinity for the ancestral (M990) sequence
compared to the derived (V990) sequence.
Consequently, we concluded that this single amino acid
change within the target epitope may reduce detection
sensitivity but would not prevent detection of L1PA2-
encoded ORF2p by this reagent. Among 31 loci previ-
ously reported to be ‘hot’ or highly active elements [48],
mAb epitopes differ by at most 1 amino acid from the
L1RP variant (Fig. 3e, and Additional file 2: Table S1),
suggesting that these youngest L1Hs sequences are likely
identifiable by all of the 5 antibodies. It is important to
note that these reference L1 sequences do not capture
all of the sequence variation within the many poly-
morphic L1 alleles that are currently segregating in hu-
man populations; these are likely close in sequence to
the L1Hs consensus but will differ by some number of
amino acids. Thus, without having actual sequence data,
our reagent may fail to bind some variants. However, we
expect that our mAbs can detect the large majority of
active L1 encoded in the human genome. We thus
probed ORF2p expression by western blot in a panel of
Fig. 3 ORF2p mAbs detect endogenous L1Hs. a Epitopes identified by five ORF2p mAbs are indicated along the linear sequence of ORF2p. b IP
blockade of ORF2p pulldown can be achieved by pre-incubating ORF2p mAbs with blocking peptides identified in (a). c ORF2p mAb epitopes
are highly conserved among both full-length and ORF2-intact L1Hs sequences in the human genome. d Western blot measuring the ability of
the MT5 antibody to detect an L1Hs polymorphism at amino acid position 990 reveals that the antibody can detect both alleles. e Epitope
%identities among 31 ‘hot’ or highly active L1Hs sequences as reported by Brouha et al. [49]. f Western blot of whole cell lysates (WCL) from
several ORF1p negative and ORF1p positive cancer cell lines fails to detect ORF2p with two different ORF2p mAbs. HEK-293TLD cells expressing
ORF2-3xFlag are included as a positive control
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cancer cell lines known to express ORF1p but were un-
able to detect it (Fig. 3f).
Characterizing L1 immunoprecipitates from CRCs
We next pursued ORF2p detection after first affinity
enriching ORF1p from tumor extracts. In our prior work
with ectopically expressed L1 RNPs in HEK-293TLD
cells, we readily co-immunoprecipitated ORF1p/ORF2p/
L1 RNA-containing macromolecules, and robustly de-
tected ORF proteins [9, 10]. The detection of ORF2p
had, at the time, been a widely recognized problem [33]
which we addressed by appending a 3xFlag epitope-tag
to the protein. The 3xFlag tag allowed us to robustly
capture and detect ORF2p. Because these experiments
provided a window on L1 biology only in an ectopic ex-
pression context, we wanted to evaluate concordance
with pathophysiology. To this end, we sought to isolate
L1 RNPs, directly from ORF1p-expressing tumors using
an anti-ORF1p affinity medium, comparing and con-
trasting the results obtained with those from our studies
of ectopic L1 expression. We obtained a cohort of CRCs
that were shown to be ORF1p positive (+) by IHC and
carried out a preliminary proteomic characterization of
three tumors selected from across the ORF1p + IHC
staining spectrum. Figure 4 shows the results we ob-
tained by multiple proteomic methods. Tumor A was
the highest ORF1p-expressing case among this group.
Tumor C was on the low-to-moderate-end of the ex-
pression spectrum and did not yield a distinct, visible
ORF1p band after IP: Fig. 4a, compare the ORF1p stain-
ing intensity in the first (far left, Tumor A), fourth
(Tumor B), and eighth (Tumor C) lanes of the gel; Fig. 4b
exhibits results obtained with Tumor A using a modified
procedure (see Fig. 4 legend and Methods). Also, see Fig.
4c for a comparison of ORF1p yield after IP from our
highest-expressing ectopic system (pLD401 [10]) to
tumors A and B. Although IP from these materials yields
ORF1p quantities that are directly comparable, side-by-
side western blotting of cell extracts revealed that
ectopic expression produced a significantly higher level
of ORF1p than these tumors (Figs. 4d ). Surprisingly and
importantly, ORF2p is only detected on our western
blots in the ectopic expression positive control (Fig. 4d,
e, and Additional file 3: Figure S4). The result did not
change when extending the blot exposure time from 2
min (Fig. 4d, shown) to 30min (not shown); nor was the
result different when using alternative anti-ORF2p
antibody clones characterized in this study. Presuming
ORF2p has been retrieved from these tumors by co-IP
with ORF1p, we conclude the yield is below the lower
limit of detection of our blotting, under the conditions
tested. Figure 4f shows cognate anti-ORF1p IHC staining
results for tumors B and C – corroborating the signal
intensity difference revealed by western blotting.
To contextualize the results obtained with CRCs,
we developed a similar analysis in a broader selection
of cell lines (Fig. 4e). We observed that the yield of
endogenous ORF1p by IP was ≲ 1/10th the amount
observed in HEK-293TLD expressing L1 ectopically
from pMT302. This construct was chosen on account
of its milder ectopic expression level. Modified from a
naturally occurring L1 sequence (L1RP), expression
from pMT302 has been estimated to yield ~ 1/40th
the L1 RNA and ORF2p and ~ 1/4th the ORF1p
expression typically observed from codon-optimized
L1 encoded by pLD401 [10, 33]. PA-1, an ovarian
teratocarcinoma cell line known to be permissive for the
expression of endogenous L1 [54], stood out among this
group - demonstrating ~ 1/10th the ORF1p yield of
pMT302 and the highest yield from an endogenous con-
text in this panel. Western blotting also demonstrated
ORF1p signal in cell lysates from the panel, but only under
probing conditions that increased high mass (nonspecific)
signal in the blot (Additional file 4: Figure S2). In this
panel, ORF2p was not detected, except by co-IP with
ORF1p from pMT302.
Believing we exhausted the potential of western blot-
ting for ORF2p detection, we turned to MS-based prote-
omic analyses. Figure 5 displays the results of a label-
free, quantitative MS analysis of affinity captured
ORF1p, from the same tumor samples displayed and an-
alyzed in Fig. 4 (see also Additional file 5: Figure S3). As
expected, we identified L1RE1 (consensus ORF1p) as a
significantly enriched protein in each IP set. Taken all
together, we observed eight other proteins that we have
previously characterized as putative physiological L1
interactors (PABPC1, PABPC4, TUBB, RO60, UPF1,
MOV10, HSP90AA1, HSP90AB1); PABPC1/4 being
most frequently recovered. We explored the interactors
discussed in [55], originating from two studies, con-
ducted by the Moran and Kazazian labs [56, 57]. We ob-
served DHX9 and MATR3 (in Tumor A, set 1),
HNRNPC and LARP1 (in Tumor A, set 2), SRSF1 (in
Tumor B, set 1 & Tumor B, set 2), SRSF6 and IGF2BP2
(Tumor B, set 2), HNRNPU (in Tumor B, set 2 &
Tumor C, set 2), and FAM120A and HNRNPA2B1 (in
Tumor C, set 2). Only HNRNPU was observed to be a
significant hit in two different patient tumors. Notably,
HNRNPU, DHX9, MATR3, HNRNPC, and other RNA
binding proteins have been reported to accumulate on
L1 and retro-element-derived RNAs; in one hypothesis,
insulating these sequences from nuclear RNA processing
pathways that might otherwise be deleterious to the
retro-element and host genes harboring these sequences
[58, 59]. The data can be summarized as follows: 291
proteins were detected as significant in one comparison
(tumor vs. control IP: p-adjusted value of ≤0.05 and log2
fold change >1), 37 passed two comparisons, and 22
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passed three comparisons; 21 ORF1p candidates with
one or more mutations from consensus ORF1p were de-
tected and of these 12 were observed in both tumor A
and tumor B. We observed a candidate phosphorylation
site at S18 (156 PSMs from this study). The next most
frequent candidate phosphorylation site, S27, received
only 31 PSMs; both S18 and S27 phospho-sites have
previously been reported [60, 61] and have been
implicated as (1) functionally important for retrotran-
sposition and (2) mediating an interaction with the
peptidyl-prolyl cis/trans isomerase PIN1. The above de-
scribed findings are further annotated and summarized
in Additional file 6: Table S2. Importantly, we did not
detect ORF2p in any of these tumor analyses.
Fig. 4 Protein Staining and Western Blotting of anti-ORF1p IPs and extracts. a Three tumors (labeled TOP, LEFT) were used as starting material for
ORF1p affinity isolations (α-ORF1p T), including mock-capture controls using mouse IgG affinity medium with tumor extracts (mIgG), and
matched normal tissue with anti-ORF1p affinity medium (α-ORF1p N). The eluted material was electrophoresed (4–12% Bis-Tris NuPAGE) and
Coomassie G-250 stained [53]; a 200 ng BSA standard is displayed as a staining intensity gauge. Each lane contains a 200 mg-scale isolation using
10 μl of affinity medium. Several bands were cut and analyzed by LC-MS/MS - the highest-ranking proteins are listed (see Methods) (b) Tumor A
anti-ORF1p affinity capture was repeated using a slightly modified procedure (see Methods). 30% of 100 mg-scale affinity isolations using 15 μl of
affinity medium have been electrophoresed and Sypro Ruby stained. c Comparison of ORF1p yield from anti-ORF1p affinity isolations. pLD401 is a
codon-optimized L1 sequence (OrfeusHs), ectopically expressed in HEK-293TLD [10]. Here, 80% of 100 mg-scale affinity isolations using 10 μl of
affinity medium have been electrophoresed and Coomassie G-250 stained. d Western blotting of the same materials used in (c), including Tumor
C and matched normal tissues. Here, 25 μg of the whole cell extract have been probed for ORF2p, ORF1p, and GAPDH as a control. 10% of α-
ORF1p affinity isolates have also been probed for ORF2p and ORF1p. e A collection of cell lines were assessed by anti-ORF1p affinity capture.
pMT302 is derived from a naturally occurring L1 sequence (L1RP), ectopically expressed in HEK-293TLD [10]. pLD222 is a plasmid harboring a
doxycycline-inducible GFP construct ectopically expressed in HEK-293TLD; here included as a control for pMT302. f IHC using α-ORF1p on (LEFT)
Tumor B and (RIGHT) Tumor C. α-ORF2p clones MT5 (panel D) and MT9 (panel E) are described in this study (see Figs. 2 and 3)
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Fig. 5 (See legend on next page.)
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The above proteomic analyses were conducted under
the assumption that these tumors will harbor somatic
retrotransposition events based on what has been re-
ported in the literature [13–17]. Nevertheless, we could
not rule out the possibility that these tumors did not ex-
press ORF2p. We therefore selected a tumor (tumor D:
a sigmoid colon cancer that metastasized to liver) and
carried out transposon insertion profiling by sequencing
(TIP-seq) [19, 22, 62] to map new insertions and estab-
lish ORF2p activity. TIP-seq analysis revealed somatic-
ally acquired insertions in the primary tumor and its
metastatic sites (data not shown). On this basis we con-
ducted co-IP/western blot analysis on the same material
in an effort to detect ORF2p (Additional file 3: Figure
S4). No ORF2p was detected, verifying that even when
new insertions are observed to occur, and when ORF1p
has first been highly enriched, ORF2p detection re-
mains challenging.
Endogenous ORF2p expression cannot presently be
directly detected in human cancers
In summary, given the lack of ORF2p detection by mass
spectrometry of tumor extracts (Fig. 1), we tested for en-
dogenous ORF2p expression in human cancers tissues
and cell lines by western blotting, IP-western, IP-MS,
and IHC (Figs. 3, 4 and 5). Western blotting and IP-
western in several widely used human cell lines express-
ing endogenous ORF1p showed no evidence of ORF2p
expression (Fig. 3f and Fig. 4e). We also conducted IHC
in human CRCs with these reagents, including cases
known to sustain somatic retrotransposition. ORF1p was
readily detectable in all cases evaluated. ORF2p immu-
nostaining, by contrast, showed no consistent signal over
isotype controls under standard conditions. Under con-
ditions employing a highly sensitive protocol, immuno-
reactivity over the isotype control was apparent only
inconsistently as cytoplasmic staining with one of the
antibodies (MT49, data not shown).
Discussion
We know that many types of human cancers accumulate
somatically acquired L1 insertions [13, 15, 17–22, 24–
26, 63, 64]. These insertions have several sequence
features that specifically indicate retrotransposition by
ORF2p; therefore, we have a high degree of confidence
that ORF2p is expressed along with ORF1p in these ma-
lignancies. As expected based on the expression level,
we reliably detect ORF1p and report co-enriching
ORF1p interactors from CRC samples. Many are pro-
teins that we and others have previously validated.
Among them, we noted the presence of nuclear RNA
binding proteins (e.g. DHX9, HNRNPU, HNRNPC,
MATR3) that have been reported by others as L1 inter-
acting proteins. The significance of these in our ORF1p
co-IPs is still debatable, particularly given data from our
group and others that ORF1p has limited role and life-
span in the nucleus in cultured cells [9, 32]: do these
represent co-assembly of ORF1p with nuclear RNAs (L1
or otherwise); are our ORF1p co-IP populations sampled
from cytoplasmic pools of heterogeneous RNAs harbor-
ing these proteins [59]; or are these proteins binding
ORF1p-containing macromolecules post-lysis (and are
therefore artifacts of spurious binding to L1 RNPs
in vitro)? Standard LFQ MS control samples, including
those used here, are not suited to rule out the latter sce-
nario. Hence, more data are needed in order to dissect
their potential significance to L1 molecular physiology.
In contrast to ORF1p, we have demonstrated that en-
dogenous ORF2p expression is difficult to reliably dir-
ectly detect in cancer samples despite strong genetic
evidence for ORF2p enzymatic activity. This is true in
the context of: (i.) highly fractionated tumor extracts
subjected to mass spectrometry-based shotgun prote-
omic analysis (as part of the CPTAC initiative); (ii.) by
employing high quality antibodies against ORF2p in
standard western blotting, immunoprecipitation, and im-
munostaining protocols; and (iii.) anti-ORF1p affinity
enrichment followed by western blotting and mass spec-
trometry. We also tried to IP ORF2p from CRC tissues
and PA-1 cells using anti-ORF2p antibodies, followed by
western blotting against ORF2p, but were unable to de-
tect ORF2p (not shown); further optimizations may alter
this outcome. While preparing this manuscript, a dataset
was released comprising anti-ORF1p co-IPs from H9 hu-
man embryonic stem cells with LFQ MS-based analysis
[65], which have been shown to exhibit strong ORF1p
expression [66]. ORF2p detection was not reported.
(See figure on previous page.)
Fig. 5 Label-free Quantitative IP-MS analysis. A legend appears at the bottom: attention is drawn to hits observed previously by I-DIRT, matches
to L1RE1 (Uniprot: ORF1p consensus), and candidate non-consensus ORF1p sequences. Gene symbols corresponding to tumor-specific, quantified
proteins are displayed on each plot with the following criteria: 1. the protein exhibited statistical significance in the IP (see Methods) with a log2
fold change ≥2 and also exhibited statistical significance in another IP from this study with log2 fold change ≥1; or 2. the protein was previously
determined specific by I-DIRT or was highlighted in other literature (discussed in the main text) and exhibited statistical significance. a Tumor A,
these IPs (set 1 and 2) differ in several experimental parameters (see Methods); both sets use a mock IP control (mouse IgG). b Tumor B, two
distinct controls were used: (LEFT) mIgG IP, (RIGHT) matched normal liver, α-ORF1p IP. c Tumor C, controls as for Tumor B with matched normal
colon. These data correspond to the IPs displayed in Additional file 5: Figure S3 and the results are collated in Additional file 6: Table S2
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ORF2p peptide detection has previously been reported
by MALDI-TOF MS after IP with an anti-ORF2p poly-
clonal antibody [67]; however, this reagent no longer ex-
ists, so further validation and side-by-side comparisons
are not possible.
From a bioinformatic perspective, the mass spectro-
metric evidence for ORF1p is strong, as several high-
quality peptide spectrum matches are observed and their
intensities are highly correlated. In contrast, only one
ORF2p peptide was observed to have reasonable PSMs
(Fig. 1d) but even these have two unexplained medium
intensity peaks – increasing the uncertainty that it con-
stitutes an observation of ORF2p. We are also hesitant
to claim that a protein is observed based on a single
relatively short peptide even if it only maps to ORF2p
and not to any other protein in the reference human
proteome, as it might map to a variant that is present in
the sample and not in the reference. In summary, the
mass spectrometric evidence for ORF2p in tumors is, at
best, questionable. We therefore recommend that
ORF2p searches of mass spectrometry data implement
additional filters to reduce the likelihood of false posi-
tives – these may include the rejection of ORF2p peptide
matches when:
1. they exhibit poor fragmentation, particularly where
the sequence differs from consensus;
2. the sequence could be explained by deamidation of
consensus sequence (D or E in variant corresponds
to N or Q in consensus, respectively);
3. the sequence could be explained by a non-tryptic
cleavage of consensus sequence; and
4. the peptide matched is not fully tryptic.
Filter 1 is not practical to carry out manually on large
data sets, but computational approaches are possible. Fil-
ters 2, 3, and 4 should be relatively straight forward to
execute programmatically in future studies. The diffi-
culty in detecting ORF2p has not been missed by the
field, yet the enthusiasm to address this challenge may
have generated some false starts (we are aware of a
newly submitted manuscript from Susan Logan and col-
leagues re-examining the reliability of the chA1-L1 anti-
body [35]). Although we cannot rule out the presence of
detectable levels of ORF2p in tumors examined by
others, failure to reliably, directly detect endogenous
ORF2 protein in the present study most likely points to
an extremely low steady state abundance for this protein
- even in the conditions of L1 de-repression that typify
these cancers - in keeping with historical estimates of
low ORF2p copy number and high ORF1p:ORF2p stoi-
chiometry [10, 31]. Commonly used ectopic expression
systems may not just overexpress ORF1p and ORF2p,
but may also skew their relative abundances and/or
apparent stoichiometry in resulting macromolecules
[10]. If this is so, whether these experimental systems
change the efficiency of ORF2p translation or over-
whelm cellular clearance pathways is unclear. In this
study we presented two direct analyses of ORF1p/2p co-
IP yields from tumors vs. ectopic expression in HEK-
293TLD cells. Firstly, consider Fig. 4d; compare ORF1p
and ORF2p signals from pLD401 to tumor A. The lower
absolute expression level and recovery of ORF1p from
tumor A suggests that the concomitant ORF2p yield by
co-IP may have been too low to expect reliable ORF2p
detection (at least, using anti-ORF2p clone 5), even at
the apparent stoichiometry described for ectopic expres-
sion in HEK-293TLD [10]. Now consider Additional file
3: Figure S4: compare ORF1p and ORF2p signals from
pMT302 to tumor D. In this case ORF1p quantities were
calibrated such that the yields from tumor D and ectopic
expression in HEK-293TLD were in a comparable range.
The result shows that, for tumor D, under these experi-
mental conditions, the recovery of ORF2p during co-IP
is relatively decreased - to below the limit of detection -
compared to ectopic expression in HEK-293TLD. Al-
though caveats may apply, a simple conclusion is as fol-
lows: either ORF2p from the tumor is less stably
associated with ORF1p under the same conditions of
capture or the intrinsic abundance of ORF2p is lower,
resulting in fewer ORF2p-containing RNPs.
Moreover, whether there is heterogeneous expression of
ORF2p in tumors has not been addressed. It is possible that
relatively rare malignant cells accumulate detectable
amounts of ORF2p, and that these have escaped sampling
in our IHC experiments. Taylor et al. previously observed
that, in the presence of robust ectopic ORF1p expression,
only a subset of cells - approximately one-third - also
exhibited ORF2p expression [10], indicating a potentially
cell-dependent stochastic determinant for ORF2p expres-
sion. Similarly, although somatic retrotransposition events
result in acquired genomic L1 insertions that are propa-
gated by the clonal expansions of tumors, we do not know
whether these accumulate continuously over time or
whether instead they reflect discrete, episodic breaches of
host defenses against L1. Indeed, there may be active selec-
tion against cells with high ORF2p because of cytotoxic ef-
fects of the protein or retrotransposition products [68, 69].
Conclusions
Here, we have evaluated L1 ORF2p expression in human
cancers using several independent and orthogonal ap-
proaches - one reliant on whole proteome analysis; one
employing a series of new, apparently avid and specific
monoclonal antibodies for ORF2p detection; and one le-
veraging ORF1p interactions to seek evidence of ORF2p.
While many types of epithelial cancers express levels of
ORF1p that are directly detectable by western blotting
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and mass spectrometry, ORF2p in these cases appears to
be only indirectly detectable by gDNA sequencing of de
novo L1 insertions. The apparent uncoupling of ORF1p
and ORF2p expression is striking, and potentially much
more pronounced in vivo than in previously character-
ized experimental systems. We expect that in the future,
more sensitive assays will reveal the now imperceptible
quantities of ORF2p. If shotgun proteomic approaches
are not sufficient to address ORF2p detection, targeted
methods can be developed to maximally leverage the
sensitivity of MS instruments (potentially ~100 s of atto-
moles [70]). Similarly, approaches such as proximity
ligation assays (PLA) or other technologies, may amplify
detection by antibodies. Characterizing ORF2p expres-
sion and understanding its regulatory mechanisms may
have translational importance. If high levels of ORF2p
expression are not compatible with malignant cell
growth, restoring expression of this protein selectively in
cancer cells producing L1 RNA and ORF1p may provide
an avenue for therapeutics.
Methods
Detection of L1 ORF peptides in CPTAC data
The CPTAC discovery breast [36] and ovarian [37] mass
spectrometry data was used (available at the CPTAC
Data Portal: https://cptac-data-portal.georgetown.edu/
cptac/s/S015 and https://cptac-data-portal.georgetown.
edu/cptac/s/S020, respectively). For the detection of
ORF1p and ORF2p peptides, we constructed a protein
sequence collection that, in addition to human proteins
from Ensembl, also included high confidence LINE-1
proteins from L1Base2 [38]: 292 ORF1p/ORF2p se-
quences translated from full-length intact LINE-1 and
107 ORF2p translated from ORF2 intact LINE-1 ele-
ments in human, and 89 LINE-1 ORF1p/ORF2p trans-
lated from ancestor consensus sequences. In addition,
we also included a list of contaminant proteins from the
common Repository of Adventitious Proteins (cRAP).
We used the X! Tandem [39] (https://www.thegpm.org/
tandem/) search engine with the curated databases and
the same search parameters as in [40]. In-house scripts
were used to parse the X! Tandem outputs to filter for
high-quality Peptide-Spectrum Matches (PSMs). Only
PSMs that meet the following criteria were retained: the
fraction of the intensity of peaks that matched the se-
quence >40%, the gaps in the fragmentation were not
larger than 3 amino acids, the peptide length > =7 and
the e-value <= 0.01. We also eliminated PSMs that
match to more than one gene. In order to select a set of
reliable peptides from ORF1p, we performed a pair-wise
comparison of the peptide quantities only kept the pep-
tides that formed a set that had a Spearman correlation
of 0.6 with each other.
Purification of ORF2 proteins
pGC6, expressing ORF2p endonuclease, is tagged with
N-HIS6-TEV. We expressed overnight in bacteria at
16°C, then shifted temperature and induced with IPTG.
We froze cell pellets then purified on a nickel column
in standard conditions. We cleaved the tag with TEV
protease overnight, then performed gel filtration to
clean up the untagged protein. pLD75, expressing
ORF2p reverse transcriptase tagged with His-MBP, was
expressed similarly, purified on a nickel column, then
with cation exchange (HiTrap SP FF; GE Healthcare
Life Sciences). pLD561, expressing full-length ORF2p-
3xFlag, was expressed as a 15 L culture in suspension
HEK-293TLD. We lysed cells with a microfluidizer in
500 mM NaCl buffer with 1% (v/v) Triton X-100, then
performed Flag IP using Dynabeads (Thermo Fisher
Scientific) coupled to anti-Flag M2 (Millipore Sigma)
followed by 3xFlag elution.
Generation of monoclonal antibodies
Rabbit monoclonal antibodies were developed with
Abcam (Cambridge, MA). For EN-targeting antibodies,
rabbits were immunized and boosted with EN, screened
by ELISA for EN affinity, and then hybridoma superna-
tants were tested against ORF2p-3xFlag by ELISA. For
RT-targeting antibodies, rabbits were immunized with
MBP-tagged RT, boosted with SUMO-tagged RT, then
screened by ELISA with MBP-RT and counter-screened
with MBP and SUMO to eliminate clones that were spe-
cific for MBP or SUMO.
ORF2p induction in HEK-293TLD cells
Plasmid DNA was miniprepped using the Zyppy Mini-
prep Plasmid DNA kit (Zymo, Irvine, CA) or PureLink
HiPure Plasmid Midiprep Kit (Thermo Fisher, Waltham,
MA). These were transfected into Tet-On HEK-293TLD
cells [10] by incubating 3 μg plasmid DNA with 9 μL
Fugene HD (Promega, Madison, WI) in 100 μL Opti-
mem for 15 min, then adding dropwise to 6-well plates
containing 500,000 cells per well. 1 μg/ml doxycycline
was added at the time of transfection and cells were then
used for immunoprecipitation, immunofluorescence, im-
munohistochemistry, or western blot assays 24 h later.
ORF1p and ORF2p immunohistochemistry
For cells, HEK-293TLD cells expressing a plasmid encod-
ing ORF2-3xFlag were admixed with untransfected
HEK-293TLD and pelleted, fixed in 10% formalin for 24
h, then processed into paraffin-embedded blocks. For
human tissue samples, de-identified paraffin-embedded
blocks were obtained from the Pathology Department at
Massachusetts General Hospital. Formalin-fixed paraffin
embedded tissues were sectioned at 5 μm onto glass
slides, heated to 65 °C for 20 min, and then rehydrated
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by serial washes in xylene, ethanol (100% / 90% / 75%),
and water. IHC was performed with the DAKO EnVi-
sion+ System-HRP kit (cat# K4006, Agilent, Santa Clara,
CA). Antigen retrieval was performed using Target Re-
trieval Solution for 20 min at >90°C, then slides were
blocked with peroxidase block and then 2% (w/v) BSA in
PBS. Primary antibody incubation with ORF1p was per-
formed at 1:5000 for 1 h at room temperature and with
ORF2p MT49 overnight at 4 °C at a final concentration
of 10 μg/ml, and secondary HRP mouse polymer second-
aries were used to label primary antibody with chromo-
gen upon DAB addition. Hematoxylin was used as a
nuclear counterstain. Slides were then dehydrated in ser-
ial washes and coverslips were placed. Scoring was per-
formed by a trained pathologist.
Immunofluorescence (IF)
HEK-293TLD cells expressing a plasmid encoding ORF2-
3xFlag were admixed with untransfected HEK-293TLD
and pelleted, fixed in 10% formalin for 24 h, then proc-
essed into paraffin-embedded blocks. IF was performed
on 5 μM sections. Slides were processed as for IHC but
using AlexaFlour-conjugated secondary antibodies (anti-
rabbit 488 and anti-mouse 555). Imaging was performed
on a Zeiss Confocal Microscope.
Antibody epitope mapping
A library of peptide based epitope mimics was synthe-
sized using solid-phase Fmoc synthesis. An amino
functionalized polypropylene support was obtained by
grafting with a proprietary hydrophilic polymer formula-
tion, followed by reaction with t-butyloxycarbonyl-
hexamethylenediamine (BocHMDA) using dicyclohexyl-
carbodiimide (DCC) with N-hydroxybenzotriazole
(HOBt) and subsequent cleavage of the Boc-groups
using trifluoroacetic acid (TFA). Standard Fmoc-peptide
synthesis was used to synthesize peptides on the amino-
functionalized solid support by custom modified JANUS
liquid handling stations (Perkin Elmer). The binding of
antibody to each of the synthesized peptides was tested
in a pepscan-based ELISA. The peptide arrays were in-
cubated with primary antibody solution (overnight at
4 °C). After washing, the peptide arrays were incubated
with a 1:1000 dilution of anti-rabbit IgG HRP conjugate
(DAKO) for 1 h at 25 °C. After washing, the peroxidase
substrate 2,2′-azino-di-3-ethylbenzthiazoline sulfonate
(ABTS) and 20 μl/ml of 3% H2O2 were added. After 1 h,
the color development was measured with a charge
coupled device (CCD) - camera and an image processing
system. Epitope targets were read as the largest contigu-
ous stretch of amino acids shared by all peptides recog-
nized by the primary antibodies.
Peptide blocking experiments
Blocking peptides were chosen to span two extra amino
acids and were N-terminally acetylated and C-terminally
amidated. Peptides were resuspended in acetic acid or am-
monium acetate depending on their charge characteristics.
To pre-block antibodies, 10, 100, or 1000-times excess
peptide by weight was incubated with primary antibody
mixture on a rotating wheel at 4 °C overnight. The next
day, pre-blocked or no-block antibodies were conjugated
to protein G dynabeads for 15min at room temperature,
then ORF2p-3xFlag HEK-293TLD lysate was added for 1 h
at room temperature. The remaining protocol is the same
as described above for immunoprecipitation.
Phage immunoprecipitation and DNA sequencing
The PhIP-Seq assay was described previously [46]. Ap-
proximately 100 ng of each mAb was added to the
combined T7 bacteriophage human peptidome library
(unique genome and repetitive element sublibrary
addition, 1 × 105 plaque forming units for each phage
clone in each library) and incubated with rotation over-
night at 4 °C in deep 96-well plates in 1mL total volume
of phosphate-buffered saline. Negative controls for data
normalization included eight mock immunoprecipitation
reactions on each plate. mAb-phage complexes were
captured by magnetic beads (20 μL of protein A-coated
and 20 μL of protein G-coated, catalog numbers 10002D
and 10004D, Invitrogen, Carlsbad, CA) for 4 h at 4 °C
with rotation and processed using the Agilent Bravo li-
quid handling system (Agilent Technologies, Santa
Clara, CA). Beads were washed twice with 0.1% NP-40
in Tris-buffered saline (50 mM Tris-HCl with 150 mM
NaCl, pH 7.5), resuspended in 20 μL of a Herculase II-
containing PCR mix (catalog number 600679, Agilent
Technologies), and ran for 20 PCR cycles followed by a
second 20-cycle PCR using 2 uL of the initial PCR prod-
ucts to add barcodes and P5/P7 Illumina sequencing
adapters. Pooled PCR products were sequenced using an
Illumina HiSeq 2500 (Illumina, San Diego, CA) in rapid
mode (50 cycles, single end reads). Data were normalized
and analyzed using a z-scores algorithm according to
Yuan et al. [71].
Cloning to generate ORF2p M990 variant
A plasmid with full-length codon-optimized L1
(pMT491) was digested with NotI-AscI, blunted with T4
polynucleotide kinase, and ligated with T4 DNA ligase
to generate a doxycycline-inducible ORF2-3xFlag ex-
pression vector (pDA033). To generate the M990 mu-
tant (Plasmid pDA101), we performed a 3-fragment
multichange isothermal assembly [72] using BsrGI/
BstZ17I-digested pDA033 as the backbone (fragment 3),
and PCR-amplified fragments containing the V990M
mutant in the overlapping sequence. PCR fragments
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were amplified from pDA033 with Q5 polymerase (NEB)
and assembly was performed with the HiFi Assembly
Master Mix (NEB). Individual clones were screened for
M990 mutations by Sanger sequencing. Fragment 1 was
generated with primers 5′-TGAGCGGCTACAAG
ATCAACGTG-3′ and 5′-GCTCATGAAGTCCTTGCC
CATGCCGATGTCCTGGATGGTG-3′. Fragment 2 was




For Figs. 4, 5, Additional file 3: Figure S4: handling of
cryomilled HEK-293TLD cells ectopically expressing L1
from pLD401 and pMT302 was previously described
[10, 73]. Patient samples were milled and extracted simi-
larly, as previously described [74]. Protein extraction so-
lution: 20 mM HEPES pH 7.4, 500 mM NaCl, 1% (v/v)
Triton X-100, 1x Roche Complete EDTA-free protease
inhibitors. Tumor A was extracted in a separate instance
in the same solution with the addition of Promega re-
combinant RNasin at 1:50 (v:v).
For patient samples subjected to LFQ-MS we used the
following parameters: 200 mg-scale, 10 μl of anti-ORF1p
(Millipore Sigma #MABC1152) and mouse IgG (Milli-
pore Sigma #I5381) affinity medium were used per 200
mg-scale affinity capture. In addition to the mouse IgG
mock affinity capture control, for tumors B and C, we
carried out an additional mock affinity capture using the
anti-ORF1p antibody and extracts from matched normal
tissue, resected at the time the CRC was removed from
the patient. Affinity media and clarified extracts were in-
cubated for 1 h at 4 °C, washed three times with extrac-
tion solution, and eluted with NuPage sample buffer
(Thermo Fisher Scientific #NP0007) at 70 °C. After SDS-
PAGE (Thermo Fisher Scientific: 1 mm, 4–12% Bis-Tris
NuPAGE system), samples were analyzed by general
protein staining, western blotting, and/or MS as de-
scribed in the main text. Samples destined for MS were
reduced (DTT) and alkylated (iodoacetamide) prior to
electrophoresis. In a second instance, tumor A affinity
isolations were conducted at a 100mg-scale using 15 μl
of anti-ORF1p and mouse IgG medium, were extracted
and washed (3 × 250 μl washes as opposed to 1 ml) in
the presence of 1:50 RNasin (not previously included),
and 1x protease inhibitors (normally only present during
extraction); approximately 2/3 the standard sonication
energy was applied (the standard is 15–20 J per 100mg-
scale in a 25% (w:v) extract). In all cases, representative
SDS-PAGE lanes are displayed in Fig. 4 and the gel plugs
used for LFQ-MS are displayed in Additional file 5: Fig-
ure S3. Unless otherwise stated, all panels displayed have
been ‘auto tone’ calibrated, respectively, in Adobe
Photoshop to maximize the visual contrast across the
detected signal range.
For Figs. 2 and 3: HEK-293TLD cells transfected with a
plasmid encoding ORF2-3xFlag were lysed by sonication
in extraction buffer (50 mM NaCl, 20 mM HEPES pH
7.4, 1% Triton, 1 mM EDTA). 1 μg of each antibody was
conjugated to 25 μL of Protein G Dynabeads for 15 min
at room temperature, then washed with TBST. IP was
carried out for 1 h at room temperature on a rotating
wheel with protein lysates diluted by TBST. For peptide
blocks, antibodies were pre-incubated with peptide, con-
jugated to Dynabeads for 15 min, and lysate was added
for 1 h at room temperature. After IP, samples were
washed in extraction buffer, then eluted from the Dyna-
beads by heating in LDS (Thermo) at 70C for 10 min.
Supernatants were then run on Mini TGX gels (Biorad)
for western blot with anti-Flag (Sigma) antibody.
Western blotting
For western blots displayed in Figs. 4 and Additional file
3: Figure S4 the following parameters were used: wet
transfer (1% [w/v] SDS / 20% [v/v] methanol in transfer
buffer) for 90 min / 70 V / 4 °C, PVDF membrane
(0.45 μm), HRP-conjugated secondary antibodies (see
below), and chemiluminescent HRP detection (substrate:
Millipore Sigma #WBLUF0100). Blocking was done
overnight at 4 °C using 5% (w/v) nonfat dry milk in
TBST (20 mM Tris-Cl, 137 mM NaCl, 0.1% Tween 20),
pH 7.6. Primary antibodies were applied overnight at
4 °C in 5% (w/v) BSA in TBST, pH 7.6. Secondary anti-
bodies were applied for 2 h at room temperature in 5%
(w/v) BSA in TBST, pH 7.6. Where appropriate, total
protein quantities were estimated using a commercial
Bradford reagent. An ImageQuant LAS-4000 system (GE
Healthcare) was used for blot imaging on the high sensi-
tivity setting with incremental image capture. ECL signal
capture times displayed varied with target from ~ 1–5
min and were free of pixel saturation in any signal dis-
played in the figures. Anti-ORF1p (Millipore Sigma
#MABC1152) was used at 0.4 μg/ml; anti-ORF2p (this
study) clone MT5 was used at 0.13 μg/ml and clone
MT9 was used at 0.71 μg/ml; anti-GAPDH (Cell Signal-
ing #2118) was used at 0.02 μg/ml. Secondary antibodies:
anti-mouse HRP conjugate (GE Lifesciences #NV931)
and anti-rabbit HRP conjugate (GE Lifesciences
#NV934) were used at 1:10,000. All panels displayed
have been ‘auto tone’ calibrated, respectively, in Adobe
Photoshop to maximize the visual contrast across the
detected signal range.
For western blots displayed in Figs. 2 and 3, cells were
lysed in RIPA buffer, vortexed, and supernatants quanti-
fied by BCA. Lysates were reduced in LDS with beta-
mercaptoethanol and then polyacrylamide gel electro-
phoresis was performed on 4–20% Protean Mini TGX
Ardeljan et al. Mobile DNA            (2020) 11:1 Page 14 of 19
gels (Biorad) and transferred to Immobilon PVDF mem-
branes for 15 min using mini TGX settings on the
Trans-Blot-Turbo system (Biorad). Membranes were in-
cubated with primary antibodies overnight at 4 °C (rabbit
anti-ORF2 mAbs at 1:1000; mouse anti-Flag M2 (Sigma
F1804) at 1:2000), secondary antibodies (all from Licor
and used at 1:10,000 dilutions; as appropriate: goat anti-
mouse IR680, goat anti-rabbit IR680, goat anti-mouse
IR800, goat anti-rabbit IR800) for 1 h at room
temperature, and detection was carried out on the Odys-
sey Scanner (Licor).
Mass spectrometry
Peptides were resuspended in 10 μL 5% (v/v) methanol,
0.2% (v/v) formic acid and half was loaded onto an
EASY-Spray column (Thermo Fisher Scientific, ES800,
15 cm × 75 μm ID, PepMap C18, 3 μm) via an EASY-
nLC 1200 interfaced with a Q Exactive Plus mass
spectrometer (Thermo Fisher Scientific). Column
temperature was set to 35 °C. Using a flow rate of 300
nl/min, peptides were eluted in a gradient of increasing
acetonitrile, where Solvent A was 0.1% (v/v) formic acid
in water and Solvent B was 0.1% (v/v) formic acid in
95% (v/v) acetonitrile. Peptides were ionized by electro-
spray at 1.8–2.1 kV as they eluted. The elution gradient
length was 10min for gel bands and 140 min for all gel
plugs except, the second set derived from tumor A,
where the gradient length was 190 min. Full scans were
acquired in profile mode at 70,000 resolution (at 200 m/
z). The top 5 (for gel bands) or 25 (for gel plugs) most
intense ions in each full scan were fragmented by HCD.
Peptides with charge state 1 or unassigned were ex-
cluded. Previously sequenced precursors were also ex-
cluded, for 4 s (for gel bands) or 30 s (for gel plugs),
within a mass tolerance of 10 ppm. Fragmentation spec-
tra were acquired in centroid mode at 17,500 resolution.
The AGC target was 2 × 105, with a maximum injection
time of 200 msec. The normalized collision energy was
24%, and the isolation window was 2m/z units.
Analysis of excised protein bands and candidate
phospho-sites
Proteins labeled in Fig. 4a selected for labeling via the
following process: The RAW files were converted to
MGF format by ProteoWizard [75] and searched against
the human protein database with X! Tandem [39], using
the following settings: fragment mass error - 10 ppm;
parent mass error - 10 ppm; cleavage site - R or K, ex-
cept when followed by P; maximum missed cleavage
sites - 1; maximum valid peptide expectation value - 0.1;
fixed modification - carbamidomethylation at C; poten-
tial modification - oxidation at M; include reversed se-
quences - yes. Parameters for the refinement search
were: maximum valid expectation value - 0.01; potential
modifications - deamidation at N or Q, oxidation or
dioxidation at M or W; unanticipated cleavage - yes. For
each protein ID list, the proteins were ranked by log E-
value; keratins, proteins ranked below trypsin, and non-
human proteins were removed; if multiple proteins
remained, the nth protein (n > 1) was removed if (a) it is
homologous to a higher-ranked protein or (b) does not
have within 50% the number of PSMs of the top-ranked
remaining protein; remaining proteins were listed as IDs
for each band. For identification of candidate phosphor-
ylation sites using X! Tandem, the RAW files from
tumor IPs (corresponding to Fig. 5) were converted to
MGF, these were searched against orthogonalized ORF
protein sequences (described below), and included the
following additional potential modifications during the
refinement search: Phospho@S, Phospho@T, Phos-
pho@Y. The best scoring PSMs for phospho S18 and
S27 are displayed in Additional file 6: Table S2. The X!
Tandem .xml output files are available via ProteomeX-
change with identifier PXD013743.
Label-free quantitative analysis
Processing RAW data in MaxQuant: we used MaxQuant
v1.6.5.0 [76, 77] with default settings and the following ad-
justments (in brief). Trypsin/P cleavage. Modifications in-
cluded in protein quantification: Oxidation (M); Acetyl
(Protein N-term); Carbamidomethyl (C). Phospho (STY)
was searched but excluded from quantification along with
unmodified counterpart peptides. Label min. Ratio count: 2.
Match between runs (within groups of cognate experiments
and controls): True. Second peptides: True. Stabilize large
LFQ ratios: True. Separate LFQ in parameter groups: False.
Require MS/MS for LFQ comparisons: True. We used a
protein database composed of the Uniprot human proteome
(reviewed), supplemented with non-redundant ORF1p and
ORF2p sequences. To increase detection sensitivity, we or-
thogonalized our ORF1 loci database (from above, Detection
of L1 ORF peptides in CPTAC data) within the context of
our detected peptides in two steps: (a) retaining loci for
which at least one unique peptide was observed and (b) in
cases that a peptide was not assigned to any loci in previous
step and was commonly shared by several loci, we included
only one representative sequence from the group, which
was the most different one to consensus ORF1 (L1RE1).
The RAW and MaxQuant processed files are available for
download via ProteomeXchange with identifier PXD013743.
Custom post-processing in R: code can be obtained at
https://github.com/moghbaie/L1_CRC_IP_MS
Data preparation
(a) Remove contaminants and reverse protein entries
(provided by MaxQuant) and IGHG1. (b) Log2 trans-
formation of LFQ MS intensities. (c) Remove proteins
with zero values across all cases and controls in a tissue.
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(d) Impute small values in scenarios that all replicates
had zero values for intensity in either cases or controls:
we calculated the average (mean) and standard deviation
(std) of non-zero values of each replicate and produced
small values with the uniform random function between
mean – 2*std. and mean – 3*std. (e) Impute values for pro-
teins that have zero intensities in one or two replicates in
either cases or controls: we built a distribution of deltas
from replicates with non-zero protein intensities: delta
¼ ðIntrep1−Intrep2ÞmeanðIntrep1;Intrep2Þ ; Calculate μdelta , sddelta; Calculate new
delta and new Intensity: deltanew ¼ rnormðmu ¼ μdelta; sd
¼ sddelta
meanðcorrelationsÞ ffiffi2p Þ
Inew ¼ mean Intotherð Þabs 1þ deltanewð Þ
Variance Analysis
(a) For tumor A, we performed t-tests between anti-
ORF1p IPs and IgG-controls. For tumor B and C, we
performed t-tests between tumor and normal tissue after
anti-ORF1p IP, as well as between tumor anti-ORF1p
IPs and IgG-controls. (b) Adjusted p-values were calcu-
lated using Benjamin-Hochberg method. (c) For each
entry log2 fold change was calculated between case and
control average intensity. (d) Significant proteins from
all comparison were integrated (p. adjusted ≤0.05 & log2
fold change ≥1). We only accept proteins with (non-im-
puted) MS intensity values in at least two experimental
replicates as candidate true positives. Therefore, proteins
that passed ANOVA but were represented by less than
two MS-derived intensity values were not considered
significant. The results are collated in Additional file 6:
Table S2.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13100-019-0191-2.
Additional file 1: Figure S1. CLUSTAL Alignments of ORF2 protein
sequences. ORF2p protein sequences were obtained from the L1Base
database of reference L1Hs sequences. (A) Alignment of 146 full-
length L1 sequences. (B) Alignment of 107 ORF2-intact L1 sequences.
In the center tiles, black bars indicate amino acid positions where
the L1 in that row differs from the CLUSTAL alignment consensus
sequence. The ‘% agreement,’ or identity, at each amino acid position
is quantified below the center tiles. On the right, the number of
amino acid changes of a particular L1 compared to the immunogen,
L1RP, is quantified.
Additional file 2: Table S1. Antibody epitope matches for 31 'hot'
L1Hs loci as described by Brouha et al, corresponding to Fig. 3e. For
each locus, we indicate whether the ORF2p sequence is identical to
the antibody epitope ("match") or whether it differs from the
epitope. For example, the hot element on ac002980 differs in the
MT5 epitope by a single amino acid (D in the antibody-derived
epitope and H at the locus). The Brouha BAC clone designation,
activity rating, and chromosomal positions are included in the chart.
Additional file 3: Figure S4. Co-IP/Western blot. Three different
segments of Tumor D were used as starting material for anti-ORF1p
affinity isolations (α-ORF1p T1–3), including a mock-capture control
using mouse IgG affinity medium with tumor extracts (mIgG T1), and
matched normal tissue with anti-ORF1p affinity medium (α-ORF1p N).
Co-IP of ORF1p/2p ectopically expressed from pMT302 in HEK-293TLD
is provided as a comparative positive control. All co-IPs used 100 mg
cells or tissues as input. 100% of the co-IP elutions done using
patient tissues were analyzed; in contrast, fractions (labeled) of the
co-IP from pMT302 in HEK-293TLD were analyzed. ORF1p yields from
Tumor D were comparable to those obtained from 1/5th – 1/10th of
a co-IP from pMT302/HEK-293TLD. However, while ORF2p signal is
clearly detectable in 1/5th and closer to the baseline (but still
eminently detectable) in 1/10th of a pMT302/HEK-293TLD co-IP, no
ORF2p signal was observed in tumor D co-IPs.
Additional file 4: Figure S2. Western blot α-ORF1p titer to detect
endogenous ORF1p in clarified cell extracts. The concentration of
α-ORF1p used is given along the top; the source of each cell extract is
given below that, and each accords to Fig. 2e. The quantity of clarified
cell extracts used, in μg total protein, follows below each extract source.
I: clarified extract used as an input for α-ORF1p affinity capture; S:
immuno-depleted extracts after incubation with α-ORF1p affinity
medium. (Left blot image) 1x α-ORF1p concentration - ORF1p signal is
observed in with ectopic expression (pMT302) and at just above back-
ground in PA-1. α-UPF1 provided as a loading control (NYU1.1B6, 1:1000
[79]). (Right blot image) 5x α-ORF1p concentration - ORF1p signal is ob-
served in all cases except HeLa Kyoto. An increase in non-specific signal
is also observed elsewhere on the blot. α-PCNA is provided as a loading
control (Santa Cruz Biotechnology, Inc. #sc-56; 1:1000).
Additional file 5: Figure S3. Coomassie G-250 stained gel plugs
used for in-gel digestion followed by MS. A panel is shown for every
replicate included in the LFQ-MS analysis. (A) Tumor A (Krukenberg
Carcinoma, Ovary) was subjected to two independent affinity isola-
tions with different parameters (see Methods). Each isolation in-
cluded three replicates using anti-ORF1p-coupled affinity medium to
capture ORF1p from the tumor extracts (Tumor A-1 to A-6), and
three replicates using mouse IgG-coupled affinity medium to sample
non-specific background from the same extracts (mIgG A Ctrl-1 to
Ctrl-6). (B) Tumor B (Metastatic Rectal Adenocarcinoma, Liver): includ-
ing three replicates using anti-ORF1p-coupled affinity medium to
capture ORF1p from the tumor extracts (Tumor B-1 to B-3), three
replicates using mouse IgG-coupled affinity medium to sample non-
specific background from the same extracts (mIgG B Ctrl-1 to Ctrl-6),
and three replicates using anti-ORF1p-coupled affinity medium to
capture ORF1p from matched normal tissue extracts (Normal B-1 to
B-3). (C) Tumor C (Adenocarcinoma, Colon): including three replicates
using anti-ORF1p-coupled affinity medium to capture ORF1p from
the tumor extracts (Tumor C-1 to C-3), three replicates using mouse
IgG-coupled affinity medium to sample non-specific background from
the same extracts (mIgG C Ctrl-1 to Ctrl-6), and three replicates using
anti-ORF1p-coupled affinity medium to capture ORF1p from matched
normal tissue extracts (Normal C-1 to C-3).
Additional file 6: Table S2. Summary of the MS-based proteomic
results, including identified and statistically significant proteins,
proteins observed in other studies, ORF1 loci detected, and phospho-
S18/S27 PSMs
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